Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin CH0012032048
Ticker ROG.VX
Company ROCHE
Currency CHF
Price
Aware Investor Index (AII) 0.0000
Recommendation STRONG SELL
P/E 0.00
ROE 30.96 %
Capitalization 0 $
Dividend Yield 0.00 %
P/S 0.00
AII Position 732
P/E Position 1
ROE Position 90
Capitalization Position 732
Dividend Yield Position 591
Sales 56,846,000,000 CHF
10-Year Average Earnings 9,400,200,000 CHF
Shares Outstanding 860,000,000
Equity 30,366,000,000 CHF
Dividend per Share 8.7 CHF
Industry Pharmaceutical
Country Switzerland
ROCHE Investor Relations Web Site http://www.roche.com/investors.htm







Sales:

YEAR MONTH AMOUNT
2018 12 56,846,000,000.00 CHF
2017 12 53,299,000,000.00 CHF
2016 12 50,576,000,000.00 CHF
2015 12 48,145,000,000.00 CHF
2014 12 47,462,000,000.00 CHF
2013 12 46,780,000,000.00 CHF

Earnings:

YEAR MONTH AMOUNT
2018 12 10,865,000,000.00 CHF
2017 12 8,825,000,000.00 CHF
2016 12 9,733,000,000.00 CHF
2015 12 8,863,000,000.00 CHF
2014 12 9,332,000,000.00 CHF
2013 12 11,164,000,000.00 CHF
2012 12 9,427,000,000.00 CHF
2011 12 9,343,000,000.00 CHF
2010 12 8,666,000,000.00 CHF
2009 12 7,784,000,000.00 CHF

Equity:

YEAR MONTH AMOUNT
2018 12 30,366,000,000.00 CHF
2017 12 29,007,000,000.00 CHF
2016 12 26,402,000,000.00 CHF
2015 12 23,300,000,000.00 CHF
2014 12 21,558,000,000.00 CHF
2013 12 21,241,000,000.00 CHF
2012 12 16,728,000,000.00 CHF
2011 12 14,482,000,000.00 CHF

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 860,000,000
2017 12 860,000,000
2016 12 860,000,000
2015 12 862,000,000
2014 12 863,000,000
2013 12 863,000,000
2012 12 848,000,000
2011 12 849,000,000

 












Bloomberg News for ROCHE:



Google News for ROCHE:

GlobeNewswire (press release) - 2 Sep 2019
Roche and Spark Therapeutics, Inc. announce extension of tender ...
Basel, 3 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today ...
Yahoo Finance - 25 Jul 2019
Edited Transcript of ROG.VX earnings conference call or ...
Half Year 2019 Roche Holding AG Earnings Call. Basel Jul 31, 2019 (Thomson StreetEvents) -- Edited Transcript of Roche Holding AG ...
Simply Wall St - 22 Jun 2019
Investors Who Bought Roche Holding (VTX:ROG) Shares A Year ...
For example, the Roche Holding AG (VTX:ROG) share price is up 26% in the last year, clearly besting than the market return of around 7.7% ...
Wall Street Journal - 28 Apr 2019
Cancer-Drug Giant Roche Loses Edge as Rivals Grow
Switzerland's Roche Holding AG has enjoyed almost two decades as an unrivaled force in oncology. Now, with more companies piling into the ...
Forbes - 4 Jun 2019
What Is Roche Holding's Fair Price Estimate Based On Expected ...
Roche Holding's (NASDAQ:RHHBY) stock price has gained 7% year-to-date, higher than a little over a 1% gain for the Dow Jones U.S. ...
PETA (blog) - 3 Jul 2019
Victory! Top 10 Pharma Company Roche Bans Forced Swim Test
After hearing from PETA, PETA Switzerland, and PETA Germany, pharmaceutical giant Roche Pharmaceuticals has just said that it's ending its ...
Forbes - 5 Jul 2019
How Much Revenues Does Roche Stand To Lose Given The FDA ...
Roche Holding's (NASDAQ:RHHBY) oncology portfolio is its largest therapeutic area, and Avastin is one of its top selling drugs. However, it is ...
The Pharma Letter - 19 Jul 2019
Roche shares hit by US biosimilar launches
Swiss pharma giant Roche (ROG: SIX) lost 2.5% of its market value on Friday morning with the arrival of competition to two of its biggest-selling ...
Seeking Alpha - 5 Feb 2019
Selling Roche: Sector And Company-Specific Reasons
I took (modest) profits in Roche ADRs very recently, for industry-related and company-specific reasons. I suspect that many Big Pharma-Biotech ...
TheStreet.com - 10 Jun 2019
Spark Therapeutics' Shares Fall on Roche Acquisition Delay
Shares of gene-therapy company Spark Therapeutics (ONCE - Get Report) fell more than 8% Monday after the company said its pending $4.3 ...


Back